Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis-Reference-Cited by-同舟云学术

Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis

Published:2024-04 Issue: Volume:202 Page:107108
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Zhang Hu,Mu Chenlu,Gu Yu,Meng Fanyi,Qin Xiali,Cao Hailong

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Reference63 articles.

1. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies;Ng;Lancet,2017

2. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study;Zhao;Aliment Pharm. Ther.,2022

3. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data;Munn;Int J. Evid. Based Health,2015

4. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience;Oussalah;Aliment Pharm. Ther.,2008

5. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab;Afif;Inflamm. Bowel Dis.,2009

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focusing on non-responders to infliximab with ulcerative colitis, what can we do first and next?;International Immunopharmacology;2024-11

2. Focusing on Non-Responders to Infliximab with Ulcerative Colitis, What Can We Do First and Next?;2024